Verge Genomics

Verge Genomics is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and human data to revolutionize drug discovery and development. The company focuses on addressing complex diseases with high unmet need by utilizing human genomics from patient disease tissues and machine learning. Notably, Verge has developed an impressive proprietary all-in-human CONVERGE® platform, featuring one of the field’s largest and most comprehensive databases of multi-omic patient data. The leadership team at Verge Genomics comprises experienced computational biologists and drug developers who are making significant strides in advancing clinical and preclinical therapeutic programs across various diseases, including ALS and Parkinson’s disease. Their commitment to diversity is evident in their proactive efforts to encourage a varied applicant pool, emphasizing a culture that does not discriminate based on race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status. Since its establishment in 2015, Verge Genomics has operated at the intersection of biotechnology, health care, and machine learning, with its headquarters based in the United States. The company's most recent milestone was the completion of a Venture Round investment on 01 July 2023, which was secured from Tenmile. This signifies a strong vote of confidence from investors as the company continues to push the boundaries of medical innovation.